OnCusp raised an oversubscribed $100 million Series A financing round in January 2024, co-led by Novo Holdings, OrbiMed, and F-Prime Capital. OnCusp is headquartered in Princeton, New Jersey.

US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported ...

Sciwind Biosciences has shared late-stage trial data for its injectable GLP-1 therapy, signaling Chinese firms’ intensifying ...

Nuvalent, a US biopharma developing precisely targeted therapies for clinically-proven kinase targets in cancer, has ...

See-sawing global tariffs, a US regulator in flux and a possible end to US drug price premia are not, apparently, enough to ...

The revision of the European pharmaceutical legislation, the reform of the Supplementary Protection Certificate (SPC) system ...

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

Danish diabetes and obesity giant Novo Nordisk yesterday announced that it will no longer be working with Hims & Hers Health ...

AI precision-medicine company Sonrai Analytics and German biotech Plectonic Biotech have entered a partnership to accelerate ...

The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with ...

Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...